

BIO-TECHNE Corp
 Form 4
 August 11, 2015

FORM 4

**UNITED STATES SECURITIES AND EXCHANGE COMMISSION
 Washington, D.C. 20549**

OMB APPROVAL

OMB Number: 3235-0287
 Expires: January 31, 2015
 Estimated average burden hours per response... 0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF SECURITIES

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934, Section 17(a) of the Public Utility Holding Company Act of 1935 or Section 30(h) of the Investment Company Act of 1940

(Print or Type Responses)

1. Name and Address of Reporting Person *
VERONNEAU MARCEL

(Last) (First) (Middle)

614 MCKINLEY PLACE N.E.

(Street)

MINNEAPOLIS, MN 55413

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
BIO-TECHNE Corp [TECH]

3. Date of Earliest Transaction
 (Month/Day/Year)
08/07/2015

4. If Amendment, Date Original Filed(Month/Day/Year)

5. Relationship of Reporting Person(s) to Issuer

(Check all applicable)

____ Director _____ 10% Owner
 Officer (give title below) _____ Other (specify below)

SVP - Clinical Controls

6. Individual or Joint/Group Filing(Check Applicable Line)
 Form filed by One Reporting Person
 ____ Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned

| 1. Title of Security (Instr. 3) | 2. Transaction Date (Month/Day/Year) | 2A. Deemed Execution Date, if any (Month/Day/Year) | 3. Transaction Code (Instr. 8) | 4. Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) | 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) | 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) | 7. Nature of Ownership (Instr. 4) |
|---------------------------------|--------------------------------------|--|--------------------------------|---|---|--|-----------------------------------|
| | | | | (A) or (D) Price | | | |
| Common Stock | | | | | 34,913 | D | |
| Common Stock | | | | | 6,827 | I | by Stock Bonus Plan |

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB control number.

SEC 1474 (9-02)

Edgar Filing: BIO-TECHNE Corp - Form 4

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
(e.g., puts, calls, warrants, options, convertible securities)

| 1. Title of Derivative Security (Instr. 3) | 2. Conversion or Exercise Price of Derivative Security | 3. Transaction Date (Month/Day/Year) | 3A. Deemed Execution Date, if any (Month/Day/Year) | 4. Transaction Code (Instr. 8) | 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4, and 5) | 6. Date Exercisable and Expiration Date (Month/Day/Year) | 7. Title and Amount of Underlying Securities (Instr. 3 and 4) | 8. Amount or Number of Shares | |
|--|--|--------------------------------------|--|--------------------------------|---|--|---|-------------------------------|----------------------------|
| | | | | Code | V (A) (D) | Date Exercisable | Expiration Date | Title | Amount or Number of Shares |
| Stock Option (Right to Buy) | \$ 62.46 | | | | | <u>(1)</u> | 07/23/2016 | Common Stock | 494 |
| Stock Option (Right to Buy) | \$ 66.25 | | | | | <u>(1)</u> | 04/29/2017 | Common Stock | 10,000 |
| Stock Option (Right to Buy) | \$ 58.4 | | | | | <u>(1)</u> | 07/29/2017 | Common Stock | 1,281 |
| Stock Option (Right to Buy) | \$ 76.15 | | | | | <u>(1)</u> | 07/27/2018 | Common Stock | 20,000 |
| Stock Option (Right to Buy) | \$ 76.15 | | | | | <u>(1)</u> | 08/27/2018 | Common Stock | 1,129 |
| Stock Option (Right to Buy) | \$ 74.05 | | | | | <u>(1)</u> | 07/26/2019 | Common Stock | 1,097 |
| Stock Option (Right to Buy) | \$ 76.02 | | | | | <u>(2)</u> | 07/31/2020 | Common Stock | 15,000 |
| Stock Option (Right to Buy) | \$ 94.35 | | | | | <u>(3)</u> | 08/12/2021 | Common Stock | 15,000 |

| | | | | | | | | |
|-----------------------------|-----------|------------|---|-------|-----|------------|--------------|-------|
| Stock Option (Right to Buy) | \$ 108.49 | 08/07/2015 | A | 7,500 | (4) | 08/07/2022 | Common Stock | 7,500 |
| Stock Option (Right to Buy) | \$ 108.49 | 08/07/2015 | A | 3,750 | (6) | 08/07/2022 | Common Stock | 3,750 |
| Restricted Stock Units | (5) | 08/07/2015 | A | 600 | (6) | (6) | Common Stock | 600 |

Reporting Owners

| Reporting Owner Name / Address | Relationships | | | |
|--|---------------|-----------|-------------------------|-------|
| | Director | 10% Owner | Officer | Other |
| VERONNEAU MARCEL 614 MCKINLEY PLACE N.E. MINNEAPOLIS, MN 55413 | | | SVP - Clinical Controls | |

Signatures

/s/ Elizabeth M. Dunshee as Attorney-in-Fact for Marcel Veronneau pursuant to Power of Attorney filed herewith.

08/11/2015

__Signature of Reporting Person

Date

Explanation of Responses:

* If the form is filed by more than one reporting person, *see* Instruction 4(b)(v).

** Intentional misstatements or omissions of facts constitute Federal Criminal Violations. *See* 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

(1) Fully exercisable.

(2) Vests 3,750 shares on each of 8/1/14, 8/1/15, 8/1/16, and 8/1/17.

(3) Vests 3,750 shares on each of 8/12/15, 8/12/16, 8/12/17, and 8/12/18.

(4) Vests 1,875 shares on each of 8/7/16, 8/7/17, 8/7/18 and 8/7/19.

(5) Each restricted stock unit represents a contingent right to receive one share of Bio-Techne common stock.

(6) Vests in full or in part if certain performance goals are achieved during each of the 2016, 2017 and 2018 fiscal years.

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, *see* Instruction 6 for procedure.

Potential persons who are to respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB number.